KLL3: Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)

Sponsor
Tampere University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01397916
Collaborator
(none)
73
1
10
7.3

Study Details

Study Description

Brief Summary

The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    73 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)
    Study Start Date :
    Feb 1, 2010
    Actual Primary Completion Date :
    Dec 1, 2010
    Actual Study Completion Date :
    Dec 1, 2010

    Arms and Interventions

    Arm Intervention/Treatment
    CLL-patients

    Controls

    Outcome Measures

    Primary Outcome Measures

    1. IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. [3 months]

      Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patients with CLL and lymphocyte count > 10 x 109/l
    Exclusion Criteria:
    • Acute infection

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tampere university Hospital Tampere Finland 33521

    Sponsors and Collaborators

    • Tampere University Hospital

    Investigators

    • Principal Investigator: Marjatta Sinisalo, MD, PhD, Tampere University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    MSinisalo, Dr, Tampere University Hospital
    ClinicalTrials.gov Identifier:
    NCT01397916
    Other Study ID Numbers:
    • CLL-IDO
    First Posted:
    Jul 20, 2011
    Last Update Posted:
    Feb 23, 2022
    Last Verified:
    Feb 1, 2022
    Keywords provided by MSinisalo, Dr, Tampere University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 23, 2022